Blockade of tumor necrosis factor-α-converting enzyme improves experimental small intestinal damage by decreasing matrix metalloproteinase-3 production in rats

Scandinavian Journal of Gastroenterology

Volumn 41, Issue 11, 2006, Pages 1320-1329

  Matsumoto, Hiroshi ^a,c   Koga, Hideki ^a,b   Iida, Mitsuo ^b   Tarumi, Ken Ichi ^a   Fujita, Minoru ^a   Haruma, Ken ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Inflammation; Matrix metalloproteinase (MMP) inhibitor; Matrix metalloproteinase (MMP) 3; Non steroidal anti inflammatory drugs (NSAIDs) induced intestinal damage; Tumor necrosis factor (TNF)

Indexed keywords

GELATINASE B; ILOMASTAT; INDOMETACIN; INTERSTITIAL COLLAGENASE; STROMELYSIN; STROMELYSIN INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME INHIBITION; HISTOPATHOLOGY; INTESTINE INJURY; INTESTINE ULCER; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SMALL INTESTINE; ZYMOGRAPHY;

ADAM PROTEINS; ANIMALS; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; ENTERITIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; ILEITIS; JEJUNAL DISEASES; MALE; MATRIX METALLOPROTEINASE 3; RANDOM ALLOCATION; RATS; RATS, WISTAR; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33750427307     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520600684571     Document Type: Article

References (42)

1. Beutler BA. The role of tumor necrosis factor in health and disease. J Rheumatol 1999;Suppl 57:16-21.
2. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997;385:729-33.
3. Moss ML, Jin SL, Milla ME, Bickett DM, Burkhart W, Carter HL, et al. Cloning of disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α. Nature 1997;385:733-5.
4. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med 1996;334:1717-25.
5. van Deventer SJ. A place of TACE. Gut 2002;51:5-6.
6. Shanahan F. Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics. Gastroenterology 2001;120:622-35.
7. Park WC, Wilson CL, Lopez-Boado YS. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 2004;4:617-29.
8. Schuppan D, Hahn EG. Matrix metalloproteinases in the gut: inflammation hits the matrix. Gut 2000;47:12-4.
9. von Lampe B, Barthel B, Coupland SE, Riecken EO, Rosewicz S. Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut 2000;47:63-73.
10. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002;295:2387-92.
11. Matsumoto T, Iida M, Kuroki F, Hizawa K, Koga H, Fujishima M. Effect of diet on experimentally induced intestinal ulcer in rats: morphology and tissue leukotrienes. Gut 1994;35:1058-63.
12. Matsumoto T, Iida M, Nakamura S, Hizawa K, Kuroki F, Fujishima M. Preventive effect of immunosuppressive agents against indomethacin-induced small intestinal ulcers in rats. Dig Dis Sci 1994;39:787-95.
13. Koga H, Aoyagi K, Matsumoto T, Iida M, Fujishima M. Experimental enteropathy in athymic and euthymic rats: synergistic role of lipopolysaccharide and indomethacin. Am J Physiol (Gastrointest, Liver Physiol) 1999;276:G576-82.
14. Tarumi K. Essential role of macrophages and macrophage-related proinflammatory cytokines in indomethacin-induced enteropathy in rats [English abstract in Japanese article]. Kawasaki Igakkaishi 2002;28:243-56.
15. Matsumoto T, Iida M, Nakamura S, Kuroki F, Hizawa K, Fujishima M. An animal model of longitudinal ulcer in the small intestine induced by intracolonically administrated indomethacin in rats. Gastroenterol Jpn 1993;28:10-7.
16. Anthony A, Pounder RE, Dhillon AP, Wakefield AJ. Similarities between ileal Crohn's disease and indomethacin experimental jejunal ulcers in the rat. Aliment Pharmacol Ther 2000;14:241-5.
17. Vilaseca J, Salas A, Guarner F, Rodriguez R, Malagelada JR. Participation of thomboxane and other eicosanoid synthesis in the course of experimental inflammatory colitis. Gastroenterology 1990;98:269-77.
18. Lindsay J, Van Montfrans C, Brennan F, Van Devenrer S, Drillenburg P, Hodgson H, et al. IL-10 gene therapy prevents TNBS-induced colitis. Gene Ther 2002;9:1715-21.
19. Heuschkel RB, MacDonald TT, Montelone G, Bajaj-Elliott M, Smith JA, Pender SL. Imbalance of stromelysin-1 and tissue inhibitor of matrix metalloproteinase (TIMP)-1 in the mucosal lesions of children with inflammatory bowel disease. Gut 2000;47:57-62.
20. Baugh MD, Perry MJ, Hollander AP, Davies DR, Cross SS, Lobo AJ, et al. Matrix metalloproteinase levels are elevated in inflammatory bowel disease. Gastroenterology 1999;117: 814-22.
21. Garcia Rodriguez LA. Variability in risk of gastrointestinal complications with different nonsteroidal anti-inflammatory drugs. Am J Med 1998;104:30S-4.
22. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004;126:1504-17.
23. Iddan G, Meron G, Glukhovsky A, Swain P. Wireless capsule endoscopy. Nature 2000;405:417.
24. Yamamoto H, Yano T, Kita H, Sunada K, Ido K, Sugano K. New system of double-balloon enteroscopy for diagnosis and treatment of small intestinal disorders. Gastroenterology 2003;125:1556-7.
25. Kirkegaard T, Hansen A, Bruun E, Bryskov J. Expression and localization of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn's disease. Gut 2004;53:701-9.
26. McKaig BC, McWilliam D, Watoson SA, Mahida YR. Expression and regulation of tissue inhibitor of matrix metalloproteinase-1 and matrix metalloproteinase by intestinal myofibroblasts in inflammatory bowel disease. Am J Pathol 2003;162:1355-60.
27. Pender SL, Tikle SP, Docherty AJ, Howie D, Wathen NC, MacDonald TT. A major role of matrix metalloproteinases in T cell injury in the gut. J Immunol 1997;158:1582-90.
28. Colon AL, Menchen LA, Hurtado O, De Cristobal J, Lizasoain I, Leza JC, et al. Implication of TNF-alpha convertase (TACE/ADAM17) in inducible nitric oxide synthase expression and inflammation in an experimental model of colitis. Cytokine 2001;16:220-6.
29. Galardy RE, Grobelny D, Foellmer HG, Fernandez LA. Inhibition of angiogenesis by the matrix metalloprotease inhibitor N-[2R-2- (hydroxamidocarbonymethyl)-4-methylpentanoyl]]-L-tryptophan methylamide. Cancer Res 1994; 54:4715-8.
30. Johnson LL, Bornemeier DA, Janowicz JA, Chen J, Pavlovsky AG, Ortwine DF. Effect of species differences on stromelysin-1 (MMP-3) inhibitor potency. An explanation of inhibitor selectivity using homology modeling and chimeric proteins. J Biol Chem 1999;274:24881-7.
31. Cheng M, De B, Almstead NG, Pikul S, Dowty ME, Dietsch CR, et al. Design and synthesis of piperazine-based, matrix metalloproteinase inhibitors. J Med Chem 1999;42: 2295-314.
32. van Deventer SJ. Transmembrane TNF-alpha, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn's disease. Gastroenterology 2001;121:1242-6.
33. Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001;121:1088-94.
34. Corazza N, Brunner T, Buri C, Rihs S, Imboden MA, Seibold I, et al. Transmembrane tumor necrosis factor is a potent inducer of colitis even in the absence of its secreted form. Gastroenterology 2004;127:816-25.
35. Sykes AP, Bhogal R, Brampton C, Chander C, Whelan C, Parsons ME, et al. The effect of an inhibitor of matrix metalloproteinases on colonic inflammation in a trinitrobenzenesulphonic acid rat model of inflammatory bowel disease. Aliment Pharmacol Ther 1999;13:1535-42.
36. Brynskov J, Foegh P, Pedersen G, Ellervik C, Kirkegaard T, Bingham A, et al. Tumor necrosis factor-alpha converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease. Gut 2002;51:37-43.
37. Bzowska M, Jura N, Lassak A, Black RA, Bereta J. Tumour necrosis factor-a stimulates expression of TNF-α converting enzyme in endothelial cells. Eur J Biochem 2004;271:2808-20.
38. Amour A, Slocombe PM, Webster A, Butler M, Knight CG, Smith BJ. TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett 1998;435:39-44.
39. Vaalamo M, Karjalainen-Lindberg ML, Saarialho-Kere U. Distinct expression profiles of stromelysin-2 (MMP-10), collagenase-3 (MMP-13), macrophage metalloelastase (MMP-12), and tissue inhibitor of MMP-3 (TIMP-3) in intestinal ulceration. Am J Pathol 1998;152:1005-14.
40. Bertrand V, Guimbaud R, Tulliez M, Mauprivez C, Sogni P, Couturier D, et al. Increase in tumor necrosis factor-a production linked to the toxicity of indomethacin for the rat small intestine. Br J Pharmacol 1998;124:138594.
41. Reuter BK,Wallace JL. Phosphodiesterase inhibitors prevent NSAID enteropathy independently of effects on TNF-α release. Am J Physiol (Gastrointest, Liver Physiol) 1999;40: G847- 54.
42. Catrina AI, Lampa J, Ernestam S, af Klint E, Bratt J, Klarekog L, et al. Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis. Rheumatology 2002;41:484-9.